High-Risk Cutaneous Squamous Cell Carcinoma
- 37 Downloads
Purpose of Review
The aim of this report is to review the literature on patients diagnosed with a “high-risk” cutaneous squamous cell carcinoma (cSCC), defined as the subset (5–10%) of cSCC patients at increased risk of developing predominantly local and/or regional recurrence and, to a lesser extent, distant metastasis.
There are no universally accepted criteria for defining or managing patients with a high-risk cSCC. We reviewed the literature and examined risk stratification, management strategies, and promising future directions. A new staging system, from the Brigham and Women’s Hospital, has provided important data on high-risk cSCC patients, highlighting the increasing risks associated with the interaction of a number of high-risk independent variables a patient has.
Only a minority of cSCC patients can be considered as high risk for developing recurrence and potentially dying from cSCC. Most patients are cured following local treatment, usually surgery. It is the high-risk patients that need to be identified and managed appropriately, often requiring multimodality treatment.
KeywordsHigh risk Nodal metastases Radiotherapy Squamous cell carcinoma
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
Human and Animal Rights and Informed Consent
All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: ● Of importance ●● Of major importance
- 4.Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.Google Scholar
- 8.Schmitt J, Haufe E, Trautmann F, Schulze H-J, Elsner P, Drexler H, et al. Is UV-exposure acquired at work the most important risk factor for cutaneous squamous cell carcinoma? Results of the population-based case-control study FB-181. Br J Dermatol. 2018;178:462–72.Google Scholar
- 9.Madeleine MM, Patel NS, Plasmeijer EI, Engels EA, Bouwes Bavinck JN, Toland AE, et al. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017;177:1208–16.Google Scholar
- 12.Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.Google Scholar
- 14.Nelson TG, Ashton RE. Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: do we need to adjust our thinking on this rare but potentially fatal event? J Surg Oncol. 2017;116:783–8.Google Scholar
- 15.•• Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20. Large prospective study examining high-risk features. CrossRefPubMedGoogle Scholar
- 16.•• Gore SM, Shaw D, Martin RCW, Kelder W, Roth K, Uren R, et al. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2016;38(Suppl 1):E884–9. The first and largest prospective study of SLNB in high-risk SCC patients indicating that local recurrence is a similar concern along with regional metastases. CrossRefPubMedGoogle Scholar
- 17.Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Man 8th ed. New York: Springer; 2017.Google Scholar
- 18.• Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419–28. Large meta-analysis examining high-risk features. CrossRefPubMedPubMedCentralGoogle Scholar
- 19.• Gupta A, Veness M, De’Ambrosis B, Selva D, Huilgol SC. Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion. Aust J Dermatol. 2016;57:3–13. Review article with suggested management pathways following the finding of perineural invasion. CrossRefGoogle Scholar
- 20.Manyam BV, Garsa AA, Chin R-I, Reddy CA, Gastman B, Thorstad W, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123:2054–60.CrossRefPubMedGoogle Scholar
- 26.Liu J, Ebrahimi A, Low T-HH, Gao K, Palme CE, Sydney C, et al. Predictive value of the 8th edition American Joint Commission Cancer (AJCC) nodal staging system for patients with cutaneous squamous cell carcinoma of the head and neck. J Surg Oncol. 2018;117:765–72.Google Scholar
- 27.Brierley J, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 2016.Google Scholar
- 28.•• Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang W-T, Gelfand JM, Whalen FM, et al. Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System. JAMA Dermat. 2013;149:402. Define the now commonly used “BWH” criteria in the alternate staging system. CrossRefGoogle Scholar
- 29.•• Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2014;32:327–34. Define the now commonly used “BWH” criteria in the alternate staging system. CrossRefPubMedGoogle Scholar
- 35.Zilberg C, Weicai Lee M, Yu B, Ashford B, Kraitsek S, Ranson M, et al. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Mod Pathol 2018;31:275–87.Google Scholar
- 42.• García-Pedrero JM, Martínez-Camblor P, Diaz-Coto S, Munguia-Calzada P, Vallina-Alvarez A, Vazquez-Lopez F, et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol. 2017;77:527–33. Are the first to examine markers of response to checkpoint inhibitors in high-risk SCC. CrossRefPubMedGoogle Scholar
- 43.• Roper E, Lum T, Palme CE, Ashford B, Ch’ng S, Ranson M, et al. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology. 2017;49:499–505. Are the first to examine markers of response to checkpoint inhibitors in high-risk SCC. CrossRefPubMedGoogle Scholar
- 44.Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608.Google Scholar
- 46.Ahadiat O, Higgins S, Sutton A, Ly A, Wysong A. SLNB in cutaneous SCC: a review of the current state of literature and the direction for the future. J Surg Oncol. 2017;116:344–50.Google Scholar
- 48.•• Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115:870–5. Important data that indicate a benefit to the addition of radiotherapy to surgery for high-risk cases following nodal surgery. CrossRefPubMedGoogle Scholar
- 50.• Baum CL, Wright AC, Martinez J-C, Arpey CJ, Brewer JD, Roenigk RK, et al. A new evidence-based risk stratification system for cutaneous squamous cell carcinoma into low, intermediate, and high risk groups with implications for management. J Am Acad Dermatol. 2018;78:141–7.. Practical guidelines for management of high-risk SCC. Google Scholar
- 55.Veness M. Hypofractionated radiotherapy in older patients with non-melanoma skin cancer: less is better. Aust J Dermatol. 2017.Google Scholar
- 60.•• Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck. 2007;29:621–31. Large Australian instituional series and analysis of high-risk features associated with metastatic nodal SCC. CrossRefPubMedGoogle Scholar
- 65.Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy. Head Neck. 2012;34:1524–8.CrossRefPubMedGoogle Scholar
- 66.•• Porceddu SV, Poulsen M, Bressel M, Stoneley A, Veness M, Kenny LM, et al. Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: a randomized phase III trial (Trans Tasman Radiation Oncology Group 05.01 Trial; POST study). J. Clin Oncol Am Soc Clin Oncol. 2017;35:6008. Outcome of a phase 3 trial, rare in this area. Google Scholar
- 67.• Oddone N, Morgan GJ, Palme CE, Perera L, Shannon J, Wong E, et al. Metastatic cutaneous squamous cell carcinoma or the head and neck. Cancer. 2009;115:1883–91. Predictive model that highlights the poor outcome of immunosuppressed patients developing metastatic cutaneous nodal SCC. Google Scholar
- 70.Papadopoulos KP, Owonikoko TK, Johnson ML, Brana I, Gil-Martin M, Perez RP, et al. REGN2810: a fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol Am Soc Clin Oncol. 2017;35:9503.Google Scholar